To hear the full episode, become a patron at patrian.com slash netpanel pod.

These studies aren't just about, you know, selling the access to the patient.

It's also about proposing and selling to the insurance company that these are therapies worth,

you know, reimbursing for.

Yeah.

And that's where the weight loss industry has had a ton of

trouble because they're not. And the insurance companies notice that. So Novo Nordisk, one thing to know is

that they're, what they're doing here in the States is, is one in other places as well. But what

they're doing is essentially using every page they can out of the Purdue

Pharma playbook that they used for OxyContin.

So they're creating AstroTurf organizations.

It's like a step-by-step guide.

And they're doing that not just here, but every.

So there's like Canada, Saudi Arabia, Australia.

Like they're doing this everywhere.

And they're having pushback because especially companies that have nationalized health care

systems are saying, no, we're not going to put your medication on our list of covered

medications because you can't prove that it creates any kind of lasting weight loss or health

benefits. And I think, too, I just want to point out that

that distinction is incredibly important because often research suggests if people can lose a little

bit of weight, then the health benefits will magically follow. And that's actually not what the

research says. So if you actually wanted to prove that these interventions work, you would have to

...